Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 101–200 of 1,001
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Olaf, M. F., & Cooney, R. R. (2017) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2017.06.003 · Cited by 138
Drug Interactions Affecting Oral Anticoagulant Use
Mar, P. L., Gopinathannair, R., Gengler, B. E., Chung, M. K., Perez, A., Dukes, J. W., Ezekowitz, M. D., Lakkireddy, D., Lip, G. Y. H., Miletello, M., et al. (2022) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.121.007956 · Cited by 150
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 120
Management of antiphospholipid syndrome
Uthman, I. W., Noureldine, M. H. A., Ruiz‐Irastorza, G., & Khamashta, M. A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213846 · Cited by 127
Long-term treatment of venous thromboembolism
Kearon, C., & Kahn, S. R. (2020) · Blood · doi:10.1182/blood.2019002364 · Cited by 127
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Cuker, A. C., & Husseinzadeh, H. D. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1185-7 · Cited by 111
“Unlike warfarin and other vitamin K antagonists, edoxaban was administered in fixed doses and did not require routine laboratory monitoring or dose adjustment in phase III clinical trials [1, 2].”
BackgroundInfluentialEvolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 128
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 116
Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Steiner, T., Weitz, J. I., & Veltkamp, R. C. (2017) · Stroke · doi:10.1161/strokeaha.116.013343 · Cited by 116
Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Skjøth, F. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0118 · Cited by 102
“In the HOKUSAI trial of venous thromboembolism treatment, a higher rate of MI was evident with edoxaban-treated patients compared to warfarin (14).”
BackgroundPrevention and Management of the Post-Thrombotic Syndrome
Makedonov, I., Kahn, S. R., & Galanaud, J. ‐. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040923 · Cited by 112
Antagonists of Vitamin K—Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives
Kasperkiewicz, K., Ponczek, M. B., Owczarek, J., Guga, P., & Budzisz, E. (2020) · Molecules · doi:10.3390/molecules25061465 · Cited by 122
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 108
Mantha, S. H., Laube, E., Miao, Y., Sarasohn, D. M. M., Parameswaran, R., Stefanik, S., Brar, G. S., Samedy, P., Wills, J., Harnicar, S. J., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1429-1 · Cited by 104
Klok, F. A., Barco, S., & Konstantinides, S. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0810 · Cited by 107
“All variables of VTE-BLEED were extracted from the study database in accordance with the definitions used in the derivation study (10).”
BackgroundMethodInfluentialIntracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Caldeira, D., Barra, M., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7462-0 · Cited by 111
Dufrost, V., Risse, J., Zuily, S., & Wahl, D. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0623-7 · Cited by 103
Evaluation of bleeding in patients receiving direct oral anticoagulants
Hellenbart, E. L., Faulkenberg, K. D., & Finks, S. W. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121661 · Cited by 114
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed Central · doi:10.2450/2015.0096-15 · Cited by 127
Moll, F. L., Baumgärtner, I., Jaff, M. R., Nwachuku, C., Tangelder, M. J. D., Ansel, G. M., Adams, G. L., Zeller, T., Rundback, J. H., GROSSO, M. A., et al. (2018) · Journal of Endovascular Therapy · doi:10.1177/1526602818760488 · Cited by 105
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Deep Vein Thrombosis of the Upper Extremity
Heil, J., Miesbach, W., Vogl, T. J., Bechstein, W. O., & Reinisch, A. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0244 · Cited by 122
Chronic complications of venous thromboembolism
Winter, M. P., Schernthaner, G.-H., & Lang, I. M. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13741 · Cited by 116
The diagnosis and treatment of venous thromboembolism in Asian patients
Wang, K.-L., Yap, E. S., Goto, S., Zhang, S., Siu, C., & Chiang, C. (2018) · Thrombosis Journal · doi:10.1186/s12959-017-0155-z · Cited by 104
“Edoxaban was as efficacious as warfarin, with respect to recurrent VTE, and had a significantly lower risk of major or CRNM bleeding [120].”
BackgroundEdoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Kreuziger, L. B., Jaffray, J., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.002 · Cited by 102
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Geldhof, V., Vandenbriele, C., Verhamme, P. B., & Vanassche, T. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-21 · Cited by 98
Hakeam, H. A., & Al-Sanea, N. A. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1465-x · Cited by 102
“5% of the DOAC recipients, respectively, had a provoked VTE, and risk factors were not determined [9, 10].”
BackgroundDirect‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 112
Stefano, V. D., Ruggeri, M., Cervantes, F., Álvarez‐Larrán, A., Iurlo, A., Randi, M. L., Elli, E. M., Finazzi, M. C., Finazzi, G., Zetterberg, E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.85 · Cited by 98
Venous thromboembolism: Recent advancement and future perspective
Yamashita, Y., Morimoto, T., & Kimura, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.08.026 · Cited by 106
The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
Mendell, J., Chen, S., He, L., Desai, M., & Parasramupria, D. A. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0298-2 · Cited by 91
“Edoxaban 60 mg was selected because it was the primary therapeutic dose used in phase 3 studies [12, 13] and is well tolerated in healthy subjects [4].”
BackgroundCancer-Associated Venous Thromboembolism in the Real World ― From the COMMAND VTE Registry ―
Sakamoto, J., Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0515 · Cited by 99
Bleeding complications during anticoagulant treatment in patients with cancer
Kamphuisen, P. W., & Beyer‐Westendorf, J. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50009-6 · Cited by 95
Wolf, S. J., Hahn, S. A., Nentwich, L. M., Raja, A. S., Silvers, S. M., & Brown, M. D. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.03.006 · Cited by 98
“Jaconelli et al(52) III Wells Unlikely Age 5 95 (86-99) 95 (86-99) 3/859 (0.”
InfluentialGoldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine · doi:10.1177/1358863x16668588 · Cited by 89
“21(6) 506 –514 © The Author(s) 2016 Reprints and permissions: sagepub.”
Mantha, S. H., & Ansell, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1102-5 · Cited by 93
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 96
“Table 1 Pharmacological properties of the DOACs Dabigatran [9, 38] Rivaroxaban [9, 40, 41] Apixaban [9, 37] Edoxaban [9, 39] Target Factor IIa Factor Xa Factor Xa Factor Xa Half-life (hour) 12-17 5-9 12 6-10 Time to peak effect (hour) 1-3 2-4 1-3 1-2 Renal clearance as unchanged drug (”
BackgroundInfluentialApixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE Trial
Loprinzi, C. L., Ashrani, A. A., Botero, J. P., Leon-Ferre, R. A., Henkin, S., Lenz, C. J., Le‐Rademacher, J. G., Wysokiński, W. E., & McBane, R. D. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0193 · Cited by 93
“The HokusaiVTE trial randomized 8240 patients with acute VTE to receive either LMWH for 5 days followed by edoxaban 60 mg once daily or warfarin (32).”
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 93
How I treat central venous access device–related upper extremity deep vein thrombosis
Rajasekhar, A., & Streiff, M. B. (2017) · Blood · doi:10.1182/blood-2016-08-693671 · Cited by 94
Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
Beyer‐Westendorf, J., Tittl, L., Bistervels, I. M., Middeldorp, S., Schaefer, C., Paulus, W. E., Thomas, W., Kemkes‐Matthes, B., Marten, S., & Bornhäuser, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30327-6 · Cited by 95
Shim, C. Y., Seo, J., Kim, Y. J., Lee, S. H., Caterina, R. D., Lee, S. H., Hong, G.-R., Shin, D., Seo, J., Lee, C. J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.01.127 · Cited by 94
Jaber, W. A., Fong, P. P., Weisz, G., Lattouf, O. M., Jenkins, J. S., Rosenfield, K., Rab, T., & Ramee, S. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.024 · Cited by 88
Vranckx, P., Lewalter, T., Valgimigli, M., Tijssen, J. G. P., Reimitz, P., Eckardt, L., Lanz, H., Zierhut, W., Smolnik, R., & Goette, A. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.009 · Cited by 92
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 94
Nopp, S., Kraemmer, D., & Ay, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903029 · Cited by 92
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
Eikelboom, J. W., Chan, N., & Bhagirath, V. C. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s63060 · Cited by 95
Cohen, A. T., Gitt, A. K., Bauersachs, R. M., Fronk, E., Laeis, P., Mismetti, P., Monréal, M., Willich, S. N., Bramlage, P., Agnelli, G., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0793 · Cited by 98
Self-citationUpdate on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 91
de Winter, M. A., Buller, H. R., Carrier, M., Cohen, A. T., Hansen, J., Kaasjager, K. A. H., Kakkar, A. K., Middeldorp, S., Raskob, G. E., Sørensen, H. T., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac776 · Cited by 91
“EINSTEIN-CHOICE was a double-blind, randomized, controlled trial comparing two doses of rivaroxaban and aspirin.14 GARFIELD-VTE was a prospective, international observational registry for long-term follow-up of VTE.15 The Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) follow…”
InfluentialNisio, M. D., Bleker, S. M., Segers, A. E. M., Mercuri, M. F., Schwocho, L. R., Kakkar, A. K., Weitz, J. I., Beyer‐Westendorf, J., Boda, Z., Carrier, M., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0452 · Cited by 83
“The edoxaban regimen was selected based on the Hokusai-VTE study (8).”
BackgroundMethodPharmacokinetics and pharmacodynamics of direct oral anticoagulants
Hindley, B., Lip, G. Y. H., McCloskey, A. P., & Penson, P. E. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2287472 · Cited by 100
“In keeping with these findings, the dose of edoxaban should be reduced in the presence of renal impairment, defined as a creatinine clearance of 15–50 mL/min [24,25,80] with numerous studies demonstrating the safety and efficacy of this approach to dosing in both AF and VTE [94–96].”
Recent advances in the discovery and development of factor XI/XIa inhibitors
Al‐Horani, R. A., & Afosah, D. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21503 · Cited by 85
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE)
Howard, L., Barden, S., Condliffe, R. A., Connolly, V. M., Davies, C. W. H., Donaldson, J., Everett, B., FREE, C. M., Horner, D. E., Hunter, L. J., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-211539 · Cited by 91
Nakamura, M., Yamada, N., & Ito, M. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.03.012 · Cited by 92
“The limitations of warfarin have stimulated the development of nonvitamin K antagonist oral anticoagulants (NOACs) for the treatment of VTE [10–13] among other indications.”
BackgroundMethodInfluentialMakam, R. C. P., Hoaglin, D. C., McManus, D. D., Wang, V., Gore, J. M., Spencer, F. A., Pradhan, R., Tran, H. V., Yu, H., & Goldberg, R. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197583 · Cited by 89
Tittl, L., Endig, S., Marten, S., Reitter, A., Beyer-Westendorf, I., & Beyer‐Westendorf, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.060 · Cited by 86
Kaikita, K., Hosokawa, K., Dahlen, J. R., & Tsujita, K. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693411 · Cited by 87
Direct Oral Anticoagulants in Patients With Active Cancer
Sabatino, J., Rosa, S. D., Polimeni, A., Sorrentino, S., & Indolfi, C. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.06.001 · Cited by 94
Clinical Evaluation of Factor XIa Inhibitor Drugs
Harrington, J., Piccini, J. P., Alexander, J. H., Granger, C. B., & Patel, M. R. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.057 · Cited by 81
Robertson, L., Kesteven, P., & McCaslin, J. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub2 · Cited by 78
Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism
Girardi, L., Wang, T.-F., Ageno, W., & Carrier, M. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318779 · Cited by 93
Edoxaban: Impact on routine and specific coagulation assays: A practical laboratory guide
Chatelain, B., Chatelain, C., Douxfils, J., Dogné, J.-M., & Mullier, F. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-05-0415 · Cited by 75
“doses were halved in case of concomitant treatment with potent P-gp inhibitors, in case of creatinine clearance (CrCl) of 30 to 50 ml/minute [min] or in case of a body weight of 60 kg or less) (1, 2).”
BackgroundStacy, Z. A., Call, W. B., Hartmann, A. P., Peters, G. L., & Richter, S. K. (2016) · Cardiology and Therapy · doi:10.1007/s40119-016-0058-2 · Cited by 77
“The Hokusai-VTE trial was a double-blind, non-inferiority trial that compared the safety and efficacy of edoxaban in the treatment of VTE [29].”
BackgroundMethodInfluentialPrins, M. H., Bamber, L., Cano, S., Wang, M. Y., Erkens, P. M. G., Bauersachs, R. M., & Lensing, A. W. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.008 · Cited by 80
Management dilemmas in acute pulmonary embolism
Condliffe, R. A., Elliot, C. A., Hughes, R. J., Hurdman, J. A., Maclean, R., Sabroe, I., van Veen, J. J., & Kiely, D. G. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-204667 · Cited by 79
Schein, J. R., White, C. M., Nelson, W. W., Kluger, J., Mearns, E. S., & Coleman, C. I. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0088-y · Cited by 89
Trujillo‐Santos, J., Micco, P. D., Dentali, F., Douketis, J. D., Díaz‐Peromingo, J. A., Núñez, M. J., Cañas, I., Mastroiacovo, D., de Sousa, M. S., Monréal, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0494 · Cited by 83
3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY
Gualandro, D., Yu, P., Caramelli, B., Marques, A., Calderaro, D., Fornari, L. S., Pinho, C., Feitosa, A. K. N., Polanczyk, C. A., Rochitte, C. E., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170140 · Cited by 91
Lutsey, P. L., Walker, R. F., MacLehose, R. F., Alonso, Á., Adam, T. J., & Zakai, N. A. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12222 · Cited by 79
Cohen, H., Doré, C. J., Clawson, S., Hunt, B. J., Isenberg, D., Khamashta, M. A., & Muirhead, N. (2015) · Lupus · doi:10.1177/0961203315581207 · Cited by 81
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 82
“Edoxaban is the only agent for which efficacy results are provided in patients with pulmonary embolism with and without right ventricular dysfunction (42).”
InfluentialBoonyawat, K., Caron, F., Li, A., Chai‐Adisaksopha, C., Lim, W., Iorio, A., Lópes, R. D., Garcia, D. A., & Crowther, M. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13701 · Cited by 79
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 81
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
“Any AE 13 (54) 4 (50) 27 (75) 15 (83) Gastrointestinal disorders 3 (13) 0 1 (3) 2 (11) General disorders and administration site conditions 6 (25) 2 (25) 5 (14) 4 (22) Infections and infestations 1 (4) 1 (13) 1 (3) 0 Injury, poisoning, and procedural complications 3 (13) 1 (13) 7 (19) 8 (44) Musculoskeletal and connec…”
Gevaert, S., Halvorsen, S., Sinnaeve, P., Sambola, A., Gulati, G., Lancellotti, P., van der Meer, P., Lyon, A. R., Farmakis, D. T., Lee, G., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab056 · Cited by 87
“Direct oral anticoagulants are increasingly used in cancer patients with atrial fibrillation and venous thromboembolism and are at least neutrally safe compared to low molecular weight heparin in both prevention and treatment of thrombosis in cancer patients.(33,34)”
BackgroundSex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
Blanco-Molina, Á., Enea, I., Gadelha, T., Tufano, A., Bura-Rivière, A., Micco, P. D., Bounameaux, H., González, J., Villalta, J., & Monréal, M. (2014) · Medicine · doi:10.1097/md.0000000000000114 · Cited by 80
“Kuijer et al found women with VTE to be at increased risk for major bleeding during the course of therapy,(15) and recent clinical trials comparing the efficacy and safety of the new anticoagulants with standard anticoagulation also revealed an increased rate of major bleeding events in women.(1,6,7,9) The lower rate…”
BackgroundResultGoggs, R. A. N., Blais, M., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E. A., & Sharp, C. R. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12801 · Cited by 86
“37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.(38-49) Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,(50-53) the overall burden of disease and the most frequently associated di…”
BackgroundThrombo-embolic prevention after transcatheter aortic valve implantation
Vranckx, P., Windecker, S., Welsh, R. C., Valgimigli, M., Mehran, R., & Dangas, G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx390 · Cited by 76
Shields, A. M., & Lip, G. Y. H. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12360 · Cited by 76
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 77
Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban
MORISHIMA, Y., & Kamisato, C. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpq2njd3pxftug · Cited by 71
Coons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Yin, O. Q. P., Kimura, T., & Miller, R. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1736-4 · Cited by 78
Freisinger, E., Gerß, J., Makowski, L., Marschall, U., Reinecke, H., Baumgartner, H., Koeppe, J., & Diller, G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa844 · Cited by 71
Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Sardar, P., Chatterjee, S., Herzog, E., Nairooz, R. S., Mukherjee, D., & Halperin, J. L. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.015 · Cited by 70
Scheres, L. J. J., Brekelmans, M. P. A., Ageno, W., Ay, C., Buller, H. R., Eichinger, S., Hutten, B. A., Klok, F. A., Middeldorp, S., Schreiber, K. I., et al. (2018) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15388 · Cited by 76
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Antonucci, E., Poli, D., Tosetto, A., Pengo, V., Tripodi, A., Magrini, N., Marongiu, F., Palareti, G., & START-Register (2015) · PLoS ONE · doi:10.1371/journal.pone.0124719 · Cited by 71
“Several phase III, non-inferiority, large trials in patients with non-valvular atrial fibrillation (NVAF)[3–6], and studies of acute[7–11]or extended [12,13] treatment in patients with venous thromboembolism (VTE) have recently been published investigating the efficacy and safety of 4 different DOAC (dabigatran, rivar…”
BackgroundNew oral anticoagulants: a practical guide for physicians
Hinojar, R., Jiménez-Natcher, J. J., Fernández‐Golfín, C., & Zamorano, J. L. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv002 · Cited by 74
Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., GROSSO, M. A., Segers, A. E. M., Meyer, G., Verhamme, P. B., Wells, P. S., Lin, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00023-5 · Cited by 68
Caldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 74
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants
Pollack, C. V., & Weitz, J. I. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0222 · Cited by 70
Risk stratification and management of acute pulmonary embolism
Becattini, C., & Agnelli, G. (2016) · Hematology · doi:10.1182/asheducation-2016.1.404 · Cited by 78
Campello, E., Spiezia, L., Simion, C., Tormene, D., Camporese, G., Valle, F. D., Poretto, A., Bulato, C., Gavasso, S., Radu, C. M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018917 · Cited by 74
“9,21 The criteria used for the classification of AT, PC, and PS defects were in line with the current literature.”
Fuentes, H. E., Tafur, A. J., & Caprini, J. A. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.03.003 · Cited by 70
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.